# Copper Histidinate Treatment for Menkes Disease

> **NCT04074512** · — · APPROVED_FOR_MARKETING · sponsor: **Sentynl Therapeutics, Inc.**

## Conditions studied

- Menkes Disease

## Interventions

- **DRUG:** copper histidinate

## Key facts

- **NCT ID:** NCT04074512
- **Lead sponsor:** Sentynl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074512, "Copper Histidinate Treatment for Menkes Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04074512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*